Pavia, Italy – January 2026 marks enGenome’s 10th anniversary, reflecting a decade of commitment to advancing genomic medicine and supporting molecular laboratories through innovation.
Founded in 2016 as a University of Pavia spin-off, enGenome has grown from a start-up providing cutting-edge solutions for genomic research into an international company, serving clinical diagnostic laboratories in more than 20 countries through its flagship platform, eVai.
“Our 10-year anniversary is a celebration of the trust our customers have in us and the dedication of our exceptional team”, said Ettore Rizzo, CEO and co-founder of enGenome. “This milestone reflects that we are still driven by curiosity, guided by the valuable feedback of our users, and committed to our responsibility toward patients.”
From its early days, enGenome has focused on one core challenge: making genomic variant interpretation more accurate and efficient. This vision led to the development of eVai, designed to increase diagnostic yield and reduce turnaround time, while ensuring scalability and regulatory compliance.
“Developing software for genomics is not just a technical challenge,” said Ivan Limongelli, CTO and co-founder. “It requires a deep understanding of laboratory and clinical workflows, in order to translate complex data into tools that are functional, intuitive and reliable for geneticists. What makes this journey truly meaningful is the collective effort of a team that combines scientific rigor with the real needs voiced by our customers.”
Innovation at enGenome has continued to evolve over time, expanding beyond variant classification to include AI-driven support for literature exploration and evidence gathering with the introduction of VarChat. This evolution reflects the company’s broader goal of supporting professionals across the entire variant assessment process.
“Innovation has consistently been our key driver” said Susanna Zucca, CSO and co-founder. “Guided by a strong focus on clinical impact, our goal is to reduce uncertainty in genomic interpretation and enable better decision-making. Reaching ten years demonstrates how solid scientific foundations, combined with continuous collaboration with users, can create solutions that truly stand the test of time.”
Looking ahead, enGenome remains focused on strengthening partnerships with laboratories, healthcare institutions and technology providers, while continuing to invest in innovation that can translate into impactful progress in clinical settings.
“Celebrating ten years is not about looking back,” Rizzo added. “It’s about continuing the journey with the purpose and values that have always defined enGenome, so we can keep driving our innovation and growth into the next decade.”
